NCT06217185
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
StatusActive, Not Recruiting
PhasePhase 4
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 19 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 1 of 5 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
PFS
Timeframe: 24months
Secondary (5)
CNS-PFS
ORR
DCR
OS
Overall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events
Arms and interventions
Experimental armExperimental
Pyrotinib, Trastuzumab Combined With Taxanes \*When taxane drugs are discontinued (after completing 6-8 cycles of treatment or due to intolerance), the therapy can be continued with the combination of metronomic capecitabine and trastuzumab, along with pyrotinib.
Drugs: Pyrotinib, Trastuzumab, Taxanes, Capecitabine
Sites
1 site in 1 country
- The Fourth Hospital of Hebei Medical UniversityShijiazhuang, Hebei, China